The CRAC channel inhibitor Synta66 reduced the levels of inflammatory cytokines IFN-γ, IL-2 and IL-17 in biopsy specimens from patients with IBD, pointing to an important role for CRAC channels in immune cell activation [40]. The gene discussed is IFNG; the disease is inflammatory bowel disease.